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Abstract
The non-steroidal compound STX modulates the hypothalamic control of core body temperature and energy homeostasis.
The aim of this work was to study the potential effects of STX on pancreatic b-cell function. 1–10 nM STX produced an
increase in glucose-induced insulin secretion in isolated islets from male mice, whereas it had no effect in islets from female
mice. This insulinotropic effect of STX was abolished by the anti-estrogen ICI 182,780. STX increased intracellular calcium
entry in both whole islets and isolated b-cells, and closed the KATP channel, suggesting a direct effect on b-cells. When
intraperitoneal glucose tolerance test was performed, a single dose of 100 mg/kg body weight STX improved glucose
sensitivity in males, yet it had a slight effect on females. In agreement with the effect on isolated islets, 100 mg/kg dose of
STX enhanced the plasma insulin increase in response to a glucose load, while it did not in females. Long-term treatment
(100 mg/kg, 6 days) of male mice with STX did not alter body weight, fasting glucose, glucose sensitivity or islet insulin
content. Ovariectomized females were insensitive to STX (100 mg/kg), after either an acute administration or a 6-day
treatment. This long-term treatment was also ineffective in a mouse model of mild diabetes. Therefore, STX appears to have
a gender-specific effect on blood glucose homeostasis, which is only manifested after an acute administration. The
insulinotropic effect of STX in pancreatic b-cells is mediated by the closure of the KATP channel and the increase in
intracellular calcium concentration. The in vivo improvement in glucose tolerance appears to be mostly due to the
enhancement of insulin secretion from b-cells.
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Introduction
The islet of Langerhans is a key tissue involved in maintaining
blood glucose homeostasis and its dysfunction is an essential factor
in the development of type 1 and type 2 Diabetes Mellitus [1,2]. In
pancreatic b-cells, ATP-sensitive potassium channels, KATP, play a
crucial role in glucose-stimulated insulin secretion. At low glucose
concentrations, KATP channels are open and the resting potential
of pancreatic b-cells remains close to 270 mV. When blood
glucose levels increase, [ATP]/[ADP] ratio rises, closing the KATP
channel. As a consequence, membrane potential depolarizes up to
about 240 mV, which opens voltage-dependent calcium chan-
nels, induces Ca
2+ influx and in turn activates insulin secretion.
This follows a pulsatile pattern as a consequence of the oscillatory
pattern in intracellular calcium concentration ([Ca
2+]i) [3–5].
Estrogens are known to be important regulators of blood
glucose homeostasis through their action on the different tissues
involved in maintaining glycemia, including the islets of Langer-
hans [6–8]. In fact, different situations characterized by a
deficiency in estrogenic activity are associated with glucose
intolerance and insulin resistance [9–12]. In addition, two
important epidemiological studies show the reduced incidence of
Diabetes in postmenopausal women following a combined
estrogen-progestin hormonal therapy [13,14]. However, the severe
side effects of this hormonal replacement therapy, such as
increased senile dementia, ovarian cancer and ischemic stroke
makes the use of estrogens as therapeutic anti-diabetic drugs
complicated [15–17].
Estrogens modulate pancreatic b-cell function through both
ERa and ERb. Physiological concentrations of 17b-estradiol exert
insulinotropic effects through ERb, while they increase insulin
biosynthesis through ERa [7,18,19]. The involvement of a yet
unknown receptor in the rapid insulinotropic effect of 17b-
estradiol has not been ruled out [19,20]. GPR30 may be involved
in the modulation of pancreatic b-cell function and survival but
only at supraphysiological concentrations of 17b-estradiol [21–23]
(for discussion see [24]).
STX is a non-steroidal diphenylacrylamide compound struc-
turally related to 4-hydroxytamoxifen [25,26]. STX has some
estrogenic properties, including the prevention of body weight gain
and the reduction in body core temperature induced by
ovariectomy in guinea pigs. In addition, STX modulates the
activity of hypothalamic POMC and dopamine neurons and
increases KATP channel activity in hypothalamic GnRH neurons
[25,27–30]. It also protects against ischemia-induced hippocampal
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34650neuron loss [31]. The effects of STX in hypothalamic neurons are
inhibited by the specific antiestrogen ICI 182,780 [27,30].
However, STX does not bind to ERa or ERb nor does it have
uterotropic effects [25]. Instead, it has been suggested to act
through a new receptor determined to be a Gq-coupled mER
[32]. Some of the actions of 17b-estradiol in hypothalamic POMC
and dopamine neurons have been also proposed to be mediated
through this Gq-coupled mER [32].
Therefore, the aim of this work is to test whether STX has
estrogenic-like effects in pancreatic b-cells and whether these
effects may be potentially useful from a therapeutic point of view.
Materials and Methods
Ethics Statement
The committee on internal animal care and use of the Miguel
Herna ´ndez University reviewed and approved all the procedures
followed (approval ID number: IB-ARL-001-10).
Materials
Fura-2AM was obtained from Molecular Probes (Invitrogen,
Barcelona). ICI 182,780 was from Tocris Cookson Ltd (Avon-
mouth, United Kingdom). STX was synthesized by a contract
research organization under the direction of Drs. Tom Scanlan
and Martin Kelly at the Oregon Health & Science University. All
other chemicals were obtained from Sigma (Madrid).
Animals
Gonadal intact adult male and female OF1 and male C57/BL6
mice were used aged 3–4months old. Females were ovariectomized
using Isoflurane (5% for induction; 1–2% for maintenance). They
were allowed to recover for at least 14 days before performing
experiments. A model for mild diabetes was used by injecting (i.p.)
C57/BL6 mice with 1 g/Kg nicotinamide and 30 min later with
150 mg/Kg streptozotocin (STZ). Nicotinamide partially protects
pancreatic b-cells against the selective cytotoxic action of STZ. This
produces a model of moderate hyperglycemia combined with the
loss of early-phase insulin secretion [33–35]. Ten days after this
treatment, surviving mice were used for in vivo experiments. All
animals were kept under standard housing conditions.
Islet and islet cells isolation
Pancreatic islets of Langerhans were isolated by collagenase
(Sigma, Madrid, Spain) digestion as previously described [36].
Freshly isolated islets were used for calcium and insulin secretion
measurements after 2 h recovery. For experiments using isolated
b-cells, islets were dispersed into single cells with trypsin. Cells
were then centrifuged and resuspended in RPMI 1640 without
phenol-red (Invitrogen, Barcelona) and with 10% charcoal
dextran-treated fetal bovine serum (Hyclone, USA), 2 mM L-
glutamine, 200 U/ml penicillin and 0.2 mg/ml streptomycin.
Cells were then plated in covers and used within 24 hours of
initiating the culture.
Recording [Ca
2+]i
Freshly isolated islets of Langerhans or isolated islet cells were
loaded with 5 mM Fura-2 AM for at least 1 hour at room
Figure 1. STX enhances glucose-induced insulin secretion in
islets from male mice following a dose-response curve. A,
Measurement of insulin secretion in isolated islets from male mice at
different STX concentrations in the presence of 8 mM glucose. The
insulin secretion in response to 16 mM glucose was used as an internal
control. Insulin secretion experiments were performed for 1 hour, in
groups of 5 islets. At least 75 islets were used per condition, from 12
different mice. B, The same as in A, but with islets from female mice. At
least 110 islets were used per condition in groups of 5, from 15 different
mice. C, Insulin secretion in response to 8 mM glucose in the absence or
presence of 10 nM STX, 1 mMo r1 0 mM ICI 182,780 as indicated.
Between 20 and 80 islets were used per condition in groups of 5, from 9
different mice. * p,0.05 vs. 8 mM glucose; # p,10
24 vs. 3m M
glucose; +p,0.05 vs. STX alone.
doi:10.1371/journal.pone.0034650.g001
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were obtained by imaging intracellular calcium under an inverted
epifluorescence microscope (Zeiss, Axiovert 200). Images were
acquired every 2 s with an extended Hamamatsu Digital Camera
C4742-95 (Hamamatsu Photonics, Barcelona, Spain) using a dual
filter wheel (Sutter Instrument CO, CA, USA) equipped with
340 nm and 380 nm, 10 nm bandpass filters (Omega optics,
Madrid, Spain). Data were acquired using Aquacosmos software
from Hamamatsu (Hamamatsu Photonics, Barcelona, Spain).
Fluorescence changes are expressed as the ratio of fluorescence at
340 nm and 380 nm (F340/F380). Results were plotted and
analyzed using commercially available software (Sigmaplot, Jandel
Scientific). Area under the curve (AUC) was measured before STX
application and during STX application after discarding the first
minute of stimulus. The time interval was 10 min for islets and
15 min for isolated cells.
Insulin secretion measurements
Freshly isolated islets were left to recover in the isolation
medium for 2 hours in the incubator. After recovery, groups of 5
were transferred to 400 ml of a buffer solution containing 140 mM
NaCl, 4.5 mM KCl, 2.5 mM CaCl2, 1 mM MgCl2,2 0 m M
HEPES and the corresponding glucose concentration with final
pH at 7.4. The islets were kept for 1 hour in the incubator.
Afterwards, 100 ml of the corresponding buffer solution with 5%
BSA was added, incubated at room temperature for 3 min and let
to cool down for 15 min on ice. Then, the medium was collected
and insulin was measured in duplicate samples by radioimmuno-
assay using a Coat-a-Count kit (Siemens, Los Angeles, CA, USA).
Insulin secretion was expressed as (mUI/islet6h). Increasing
concentrations of glucose were used as internal controls. Fasting
glucose levels were used to test the compound (7–8 mM for mice:
[37]).
Patch-clamp recordings
KATP channel activity was recorded using standard patch clamp
recording procedures from isolated pancreatic b-cells cells.
Currents were recorded using an Axopatch 200B patch-clamp
amplifier (Axon Instruments Co. CA, USA). Patch pipettes were
pulled from borosilicate capillaries (Sutter Instruments Co. CA,
USA) using a Flaming/Brown P-97 micropipette puller (Sutter
Instruments Co. CA, USA) with resistance between 3–5 MV when
filled with the pipette solution as specified below. Bath solution
contained (in mM): 5 KCl, 135 NaCl, 2.5 CaCl2, 10 Hepes and
1.1 MgCl2 (pH 7.4) and supplemented with glucose as indicated.
The pipette solution contained (in mM): 140 KCl, 1 MgCl2,1 0
Hepes and 1 EGTA (pH 7.2). The pipette potential was held at
0 mV throughout recording. KATP channel activity was quantified
by digitising 60 s sections of the current record, which was filtered
at 1 kHz and sampled at 10 kHz by a Digidata 1322A (Axon
Instruments Co. CA, USA), and calculating the mean open
probability of the channel (NPo) during the sweep. Channel activity
was defined as the product of N, the number of functional
channels, and Po, the open-state probability. Po was determined by
dividing the total time channels spent in the open state by the total
sample time. Data sampling was started 1 min before (control) and
5 min after application of test substances. Experiments were
carried out at room temperature (20–24uC).
Short-term treatment with STX
Mice were placed in separate cages the evening before the
experiment. A single dose of 100 mg STX/kg body weight was
inoculated in a volume of 150 ml saline solution just before the
corresponding tests. For the Intraperitoneal Glucose Tolerance
Test (IPGTT) mice fasted for 15 hours and 2 g glucose/kg body
weight was injected. The Insulin Tolerance Test (ITT) was
performed in the morning at 10 am and a dose of 1 UI insulin/kg
body weight was used. All the injections were intraperitoneal.
Blood glucose was obtained from the tail vein using an Accu-check
portable glucometer (Roche Diagnostic GmbH, Mannheim,
Germany). For glucose sensitivity, we quantified the glycemic
response measuring the incremental area under the curve (AUC)
[38,39]. In a different set of experiments, plasma insulin was
quantified 30 min after the glucose load as for the IPGTT. For
this, mice were anesthetized with pentobarbital and blood was
obtained by cardiac puncture with a syringe containing EDTA.
Figure 2. STX enhances calcium entry in islets and isolated b-
cells. A, [Ca
2+]i recording of an islet of Langerhans in the presence of
8 mM glucose; 10 nM STX was added to the perfusion when indicated;
n=11 islets from 3 different male mice. B, [Ca
2+]i recording of an
isolated pancreatic b-cell in the presence of 8 mM glucose; 10 nM STX
was added to the perfusion when indicated. C, Area under the curve in
[Ca
2+]i recordings from isolated b-cells. * p,0.000005; n=100 cells from
3 different male mice.
doi:10.1371/journal.pone.0034650.g002
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ultrasensitive mouse insulin assay kit from Mercodia AB (Uppsala,
Sweden).
Long-term treatment with STX
Mice were injected intraperitoneally in the morning with a daily
dose of 100 mg STX/kg body weight for 6 days. On the evening of
the 6
th day, body weight was measured. On the morning of the 7
th
day, an IPGTT was performed as described previously and islets
were isolated from those mice. These islets were lysed in an
ethanol/HCl buffer immediately after isolation. They were kept
overnight at 4uC, the supernatant was collected by centrifugation
the following day and the insulin content was measured using RIA.
Statistical analysis
Data are expressed as mean 6 SEM. Student’s t-test was used
for statistical comparison, unless otherwise stated. A probability
level of 0.05 or lower was considered statistically significant.
Results
STX enhances glucose-induced insulin secretion in islets
from male mice in an ICI 182,780-dependent manner
We first determined whether STX was capable of modulating
pancreatic b-cell function. For this purpose, we performed
separate insulin secretion experiments for islets from male and
female mice. We observed that 1–10 nM STX produced an
increase in glucose-induced insulin secretion in isolated islets from
male mice by 24% and 31%, respectively, while 100 nM STX had
no effect (Fig. 1A). However, this potentiating effect of STX was
not obtained in islets from intact female mice (Fig. 1B). The
specific anti-estrogen ICI 182,780 partially inhibited the insulino-
tropic effect of STX at 1 mM, while it completely blocked STX
effects at 10 mM (Fig. 1C). Therefore, low concentrations of STX
enhance glucose-induced insulin secretion in islets from male mice
in an ICI 182,780-dependent manner.
STX increases calcium entry into b-cells
Since insulin secretion is a calcium-driven event, we studied the
effects of STX on [Ca
2+]i in isolated islets of Langerhans from
male mice. 10 nM STX altered [Ca
2+]i in response to 8 mM
glucose (Fig. 2A). The total calcium entry into the islets in response
to 8 mM glucose in the absence or presence of 10 nM STX was
quantified as the area under the curve (AUC). STX increased
AUC in islets of Langerhans by 24%. We also recorded [Ca
2+]i in
isolated b-cells (Fig. 2B). Similar to the effect in whole islets, STX
increased calcium entry in the presence of 8 mM glucose in
isolated b-cells (Fig. 2B, C). Therefore, 10 nM STX modulates
intracellular calcium concentrations by increasing calcium influx
into pancreatic b-cells.
STX modulates the KATP channel activity in pancreatic b-
cells
As mentioned previously, KATP channels are key to regulating
glucose-induced insulin secretion. Therefore, we decided to study
whether the insulinotropic effect of STX in islets from male mice
was mediated by the regulation of the channel activity. For this
purpose, cell-attached recordings of isolated b-cells were per-
formed in the absence of glucose (Control, Fig. 3A). The addition
Figure 3. STX decreases the KATP channel activity. A, A cell-
attached patch-clamp recording of a representative isolated b-cell is
shown. Several seconds of the same recording are shown at different
moments of the experiment. B, The open probability (NP0) of the KATP
channel during Control (0 mM glucose), 10 nM STX, 8 mM glucose and
100 mM Diazoxide (Diaz) was measured. C, The open probability (NP0)o f
the KATP channel during Control (0 mM glucose), 100 mM Diazoxide
(Diaz) and Diazoxide plus 10 nM STX (Diaz+STX). * p,0.05, ** p,0.01,
# p,0.005, +p,0.00005 vs. Control; n=11 cells from 5 different male
mice.
doi:10.1371/journal.pone.0034650.g003
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the KATP channel (Fig. 3A–B). This decreased represented 43% of
the activity of the channel in the absence of glucose (Control).
Channels were perfectly functional after washout of STX, since
they responded to 8 mM glucose and to the KATP opener
diazoxide as expected (Fig. 3A–B). In addition, diazoxide
prevented the decrease in activity elicited by STX as shown in
figure 3C. Therefore, 10 nM STX modulates the activity of the
KATP channel in pancreatic b-cells.
In vivo administration of STX improves glucose tolerance
in male mice
As mentioned above, pancreatic b-cells are important to
maintain blood glucose homeostasis, particularly glucose sensitiv-
ity. Given the insulinotropic effect of STX in islets from male mice
ex vivo, we analyzed the rapid effect of STX on glucose tolerance.
For this purpose, overnight fasted male mice were injected with a
single i.p. injection of STX (100 mg/kg) in conjunction with a
glucose challenge of 2 g/kg (IPGTT). As shown in Figure 4A,
glycemia in response to a glucose load after STX administration
did not reach the values obtained with vehicle. Glycemia at 30 and
60 min were significantly decreased and the area under the curve
(AUC) was also reduced with STX (Fig. 4B). We also performed
experiments in female mice, and STX only improved glucose
tolerance at 30 min (Fig. 4C), while AUC did not reach statistical
significance (p=0.07) (Fig. 4D). Therefore, we conclude that STX
rapidly modulates glucose tolerance in male mice, with only a mild
effect in females.
STX increases plasma insulin in response to a glucose
load in male mice
Changes in glycemia during an IPGTT are the result of the
balance between insulin secretion by the endocrine pancreas and
insulin sensitivity in peripheral tissues. To decipher the main
component responsible for the increase in glucose tolerance by
STX, we measured plasma insulin 30 min after the glucose load
and STX administration. In agreement with the insulin secretion
experiments, plasma insulin concentration was increased in mice
treated with 100 mg STX/kg body weight (Fig. 5A). In addition,
we performed an Insulin Tolerance Test (ITT), and we found that
STX slightly increased insulin sensitivity, although this effect was
mild and statistically significant only at 60 min (Fig. 5B). We also
Figure 4. STX improves glucose sensitivity in male mice. A, Intraperitoneal glucose tolerance test (IPGTT) in male mice after injection of
Vehicle (N) or 100 mg/kg STX (#). B, Area under the curve in the IPGTT in males; n=6–7 mice/condition. C, IPGTT in female mice. D, Area under the
curve in the IPGTT in females; n=7 mice/condition. * p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0034650.g004
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did not alter plasma insulin after the glucose load, and insulin
resistance was only improved at 15 min (Fig. 5C, D). Therefore,
STX rapidly modulates blood glucose homeostasis in male mice
mainly by enhancing the plasma insulin response to glucose.
STX does not alter glucose homeostasis or insulin
content after long-term treatment
Our next aimwas tostudy theconsequences of adailydose of STX
on blood glucose homeostasis. For this purpose, we injected male
mice with a daily dose of 100 mg/Kg body weight for 6 days. This
treatment did not alter body weight or fasting glucose levels (Fig. 6A–
B). We then performed IPGTT and it was not modified by treatment
with STX (Fig. 6C). In addition, insulin content in pancreatic islets
was unaltered as shown in Fig. 6D. Therefore, STX at this low dose
does not affect body weight, fasting glycemia or IPGTT in male mice
or insulin content in pancreatic islets after a 6 day-treatment.
STX does not alter glucose homeostasis in
ovariectomized females
In view of the gender-specific effect of STX in males, we
wondered whether this was due to the presence of 17b-estradiol in
the females. Therefore, we studied the effect of STX in
ovariectomized (OVX) females. The experiments were performed
14 days after ovariectomy. As in intact females, a single dose of
100 mg/Kg STX failed to alter blood glucose homeostasis as
shown in figures 7A–B. We then treated OVX females for 6 days
with a daily dose of 100 mg/Kg STX. As in males, the compound
did not alter body weight (Fig. 7C). In addition, fasting glycemia
and IPGTT performed on the morning of the seventh day were
not modified by STX (Fig. 7D–E). Insulin content from isolated
islets was indifferent to the 6-day treatment with 100 mg/Kg STX
(Fig. 7F). Therefore, STX does not alter blood glucose homeostasis
in ovariectomized females, either after an acute or a long-term
treatment with a 100 mg/Kg dose of STX.
STX does not improve glucose homeostasis in a mice
model of mild diabetes
Given the insulinotropic effect of STX ex vivo and the
improvement of glucose tolerance in vivo, we decided to study
the importance of these effects in a situation of b-cell dysfunction.
For this purpose, we used a model of mild diabetes induced with
nicotinamide and streptozotocin (STZ). Ten days after this
treatment, surviving mice were tested for glucose intolerance
Figure 5. STX increases glucose-induced plasma insulin levels. A, Plasma insulin concentration (mg/l) measured at 30 min after a 2 g/kg
glucose load in male mice treated with vehicle or 100 mg/kg STX; n$7 mice/condition. B, Insulin tolerance test (ITT) in male mice after treatment with
vehicle or 100 mg/kg STX; n=11 mice/condition. C, Plasma insulin concentration (mg/l) measured at 30 min after a 2 g/kg glucose load in female mice
treated with vehicle or 100 mg/kg STX; n=5–6 mice/condition. D, Insulin tolerance test (ITT) in female mice after treatment with vehicle or 100 mg/kg
STX; n=7–8 mice/condition. * p,0.05, ** p,0.01.
doi:10.1371/journal.pone.0034650.g005
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groups, one receiving a daily i.p. injection of vehicle, the other
100 mg/Kg STX, for 6 days. As shown in Figure 8B, the 6-day
treatment with this dose of STX reduced hyperglycemia, although
not significantly (p=0.08), while treatment did not improve
glucose tolerance in mice tested on the morning of the seventh
day.
Discussion
In this work we show that low concentrations of STX rapidly
enhanced glucose-induced insulin secretion in islets, increased
calcium response to glucose and closed the KATP channels in
pancreatic b-cells. That the effect of STX is direct on b-cells is
indicated by the calcium and patch-clamp experiments performed
in isolated cells. The insulinotropic effect of STX was only
produced in islets from male mice, while no effect was obtained in
islets from female mice. In addition, the anti-estrogen ICI 182,780
blocked the insulinotropic effect of STX. In vivo, STX improved
glucose tolerance and enhanced glucose-induced plasma insulin
levels in male mice, with only a slight increase in insulin sensitivity.
In females, the effect on blood glucose homeostasis was quite
modest and no change was observed in plasma insulin in response
to the glucose load or insulin sensitivity. After a 6 day-treatment
with a low dose, STX did not modify body weight, glucose
tolerance or islet insulin content. STX was also ineffective in
modifying glucose homeostasis in ovariectomized females either
after an acute dose or a long-term treatment. It did not improve
glucose homeostasis in male mice from a model of glucose
intolerance after 6 days of treatment.
The data presented here suggest that STX has a gender-specific
effect in modulating pancreatic b-cell function. This insulinotropic
effect of STX in pancreatic b-cells from male mice may be
mediated by the closure of KATP channels and the increase in
intracellular calcium concentration observed. The in vivo improve-
ment in glucose tolerance in males after an acute dose appears to
be mostly due to the enhanced insulin secretion in b-cells.
Physiological concentrations of the endogenous hormone 17b-
estradiol have been reported to increase insulin secretion in
pancreatic islets of Langerhans. This effect is mediated by the
modulation of the KATP channel activity and calcium signaling
[2,40]. In addition, 17b-estradiol attenuates the glycemic response
Figure 6. STX does not alter insulin content or blood glucose homeostasis at long-term in male mice. A, Body weight in male mice
before and after the 6 day-treatment with either vehicle or STX; n=5 mice/condition. B, Fasting glycemia in the following morning after the 6-day
treatment with vehicle or STX treated mice (n=5 mice/condition). C, IPGTT in the same mice as in B; vehicle (N), STX (#); n=4–5 mice/condition. D,
Insulin content in isolated islets from vehicle and STX-treated mice; n=60–120 islets from 2–3 mice/condition.
doi:10.1371/journal.pone.0034650.g006
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e34650Figure 7. STX does not change glucose homeostasis in ovariectomized female mice. A, Intraperitoneal glucose tolerance test (IPGTT) in
ovariectomized female mice after one single dose of vehicle (N) or 100 mg/kg STX (#). B, Area under the curve in the IPGTT in A; n=7–8 mice/
condition. C, Body weight in ovariectomized female mice before and after the 6 day-treatment with either vehicle or STX; n=5–6 mice/condition. D,
Fasting glycemia in the following morning after the 6-day treatment with vehicle or STX treated mice (n=5–6 mice/condition). E, IPGTT in the same
mice as in D; vehicle (N), STX (#); n=5–6 mice/condition. F, Insulin content in isolated islets from vehicle and STX-treated ovariectomized female
mice; n=110–140 islets from 4–6 mice/condition.
doi:10.1371/journal.pone.0034650.g007
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similar doses of STX mimic the effects of 17b-estradiol on insulin
secretion ex vivo in islets from male mice. In addition, STX also
improves glucose tolerance in vivo in response to a glucose load.
However, differences exist between the actions of 17b-estradiol
and STX. On one hand, 17b-estradiol has proven to be effective
in islets from both males and females [19,36], while STX is only
effective in males. On the other hand, 17b-estradiol increases
insulin content and produces mild glucose intolerance after 4 days
of treatment [41], while STX does not alter these parameters after
a 6-day treatment. In addition, the insulinotropic effect of 17b-
estradiol is mediated by ERb, while STX does not bind to this
receptor. In spite of this, the effect of STX in pancreatic b-cells, as
in hypothalamic neurons [27,30], is blocked by the selective
estrogen receptor antagonist ICI 182,780, suggesting a novel
estrogen receptor involved.
Blood glucose homeostasis is maintained by the interplay of
several tissues: liver, brain, adipose tissue, skeletal muscle and the
endocrine pancreas. Pancreatic b-cells are key regulators of
glucose tolerance and proper b-cell function is essential to
maintain blood glucose homeostasis [1]. Within the brain, the
hypothalamus is involved in glucose and energy homeostasis [42].
Indeed, insulin directly infused into the arcuate nucleus of the
hypothalamus (ARC) reduces hepatic glucose production, an effect
that is inhibited with KATP blockers [43]. Activation of
hypothalamic KATP channels lowers plasma glucose through
inhibition of hepatic gluconeogenesis [44]. STX has been shown
to modulate the activity of hypothalamic neurons, particularly
dopamine and POMC neurons, as well as the activity of KATP
channels in GnRH neurons [25,27,28,30]. STX, along with 17b-
estradiol, prevents weight gain after ovariectomy in guinea pigs,
probably due, in part, to a decrease in food intake [27,29,45].
Therefore, all these findings suggest that STX may have a broader
impact on blood glucose homeostasis not only through its effects
on pancreatic b-cell function, but also through the modulation of
hypothalamic neurons controlling energy homeostasis [27,29].
Data presented here show that 100 mg/Kg STX improves
glucose homeostasis in male mice after one dose administered at
the same time as a glucose load. However, no effect is observed
24 hours after the cessation of a 6-day treatment with the same
dose, either in normal mice or in a model of mild diabetes. The
reason for these differences may be the pharmacokinetics of the
compound, which have not been extensively studied. In fact, the
pharmacokinetic properties determine the administration frequen-
cy of insulinotropic anti-diabetic drugs such as sulphonylureas and
glinides, both KATP channel blockers [46,47]. Glinides, for
example need to be administered more frequently during the
day than sulphonylureas due to their shorter circulating half-life
[47]. In addition, the precise time of the administration may
change the glucose-lowering effects of these drugs, as in the case of
tolbutamide [48]. Indeed, in guinea pigs, the least observable
effective concentration (LOEC) of STX for modulation of energy
homeostasis is 2 mg/kg [27].
In this work we show the gender-specific effect of STX in mice.
While 100 mg/Kg STX improves glucose homeostasis in male
mice, females are insensitive even after ovariectomy. The lack of
effect with STX after ovariectomy suggests that the differences are
not due to circulating estrogens, but rather to developmental
differences that are not reversed post-ovariectomy, similar to the
loss of the leptin receptor in POMC neurons [49]. Gender-specific
differences are not uncommon in metabolism. There is evidence
that insulin sensitivity differs between males and females [50,51].
Moreover, many studies have shown that women have lower
diabetes prevalence than men [11,52–54]. In diverse animal
models of glucose intolerance, insulin resistance and diabetes,
males show a stronger phenotype than females [55,56]. Therefore,
it is not surprising that the response to drugs aimed at metabolic
targets depend on the sex, as it is in the case with STX. In fact,
men and women respond differently to some medications and
therapeutics [57].
In summary the work presented here is the first approach to a
full characterization of STX as a potential anti-diabetic agent.
Since STX has no uterotropic effects and does not bind to ERa or
ERb, it may be a novel SERM with the beneficial effects of
estrogen therapy without many of the deleterious side effects.
Figure 8. Long-term treatment with STX does not improve
glucose homeostasis in a model of mild diabetes. A, IPGTT in
control mice or treated with nicotinamide and streptozotocin (STZ) to
generate glucose intolerance. B, IPGTT in the same mice after 6 days
treatment with either vehicle (ControlN; STZ-Vehicle .) or 100 mg/Kg
STX (STZ-STX #); n=5–8 mice/condition; * p,0.005; ** p,0.001; #
p,0.0005; p=0.08 STZ-STX vs. STZ-Vehicle at 0 min (fasting glycemia).
doi:10.1371/journal.pone.0034650.g008
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